Analyst: Positive results from Ambu's Duodeno 1.5 reflected in Ambu shares

Today's positive results from Ambu's clinical study with its new and improved duodenoscope product, the Ascope Duodeno 1.5, have been received well by investors, who have sent Ambu's share price up, as observed by Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app